These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 28985766)

  • 41. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
    Kwong A; Shin VY; Ho JC; Kang E; Nakamura S; Teo SH; Lee AS; Sng JH; Ginsburg OM; Kurian AW; Weitzel JN; Siu MT; Law FB; Chan TL; Narod SA; Ford JM; Ma ES; Kim SW
    J Med Genet; 2016 Jan; 53(1):15-23. PubMed ID: 26187060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
    Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
    J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
    Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer susceptibility: current knowledge and implications for genetic counselling.
    Ripperger T; Gadzicki D; Meindl A; Schlegelberger B
    Eur J Hum Genet; 2009 Jun; 17(6):722-31. PubMed ID: 19092773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study.
    Meisel C; Sadowski CE; Kohlstedt D; Keller K; Stäritz F; Grübling N; Becker K; Mackenroth L; Rump A; Schröck E; Arnold N; Wimberger P; Kast K
    Arch Gynecol Obstet; 2017 May; 295(5):1227-1238. PubMed ID: 28324225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
    Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
    Golmard L; Delnatte C; Laugé A; Moncoutier V; Lefol C; Abidallah K; Tenreiro H; Copigny F; Giraudeau M; Guy C; Barbaroux C; Amorim G; Briaux A; Guibert V; Tarabeux J; Caputo S; Collet A; Gesta P; Ingster O; Stern MH; Rouleau E; de Pauw A; Gauthier-Villars M; Buecher B; Bézieau S; Stoppa-Lyonnet D; Houdayer C
    Oncogene; 2016 Mar; 35(10):1324-7. PubMed ID: 26028024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
    Agata S; Viel A; Della Puppa L; Cortesi L; Fersini G; Callegaro M; Dalla Palma M; Dolcetti R; Federico M; Venuta S; Miolo G; D'Andrea E; Montagna M
    Genes Chromosomes Cancer; 2006 Sep; 45(9):791-7. PubMed ID: 16715518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary results of targeted sequencing of
    Saied MH; Elkaffash D; Fadl R; Haleem RA; Refeat A; Ibrahim I; Tahoun M; Elkayal A; Tayae E
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34296289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.
    Dutil J; Golubeva VA; Pacheco-Torres AL; Diaz-Zabala HJ; Matta JL; Monteiro AN
    Breast Cancer Res Treat; 2015 Dec; 154(3):441-53. PubMed ID: 26564481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
    Kadouri L; Kote-Jarai Z; Easton DF; Hubert A; Hamoudi R; Glaser B; Abeliovich D; Peretz T; Eeles RA
    Int J Cancer; 2004 Jan; 108(3):399-403. PubMed ID: 14648706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breast cancer susceptibility variants alter risks in familial disease.
    Latif A; Hadfield KD; Roberts SA; Shenton A; Lalloo F; Black GC; Howell A; Evans DG; Newman WG
    J Med Genet; 2010 Feb; 47(2):126-31. PubMed ID: 19617217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
    Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
    Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.